Categories
Onesource Specialty Pharma Limited — Updates, 13-05-2026: Press Release
13-05-2026 · 01:40 pm
OneSource saw strong Q4FY26 performance with Revenue at ₹428.2 Cr (+47% QoQ) and EBITDA at ₹91.9 Cr (5x+ QoQ), driven by semaglutide launches. It reaffirms FY28 guidance of ~₹3596 Cr organic revenue and 40% EBITDA margin. Steriscience asset acquisition is paused until post FY28.
No comments yet. Be the first to comment!